Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.

导出 LinkOut

翻译打印收藏纠错

作者： L T,Domingo ^[1] ; D D,Ivy ^[2] ; S H,Abman ^[2] ; A M,Grenolds ^[2] ; J T,MacLean ^[2] ; J A,Breaux ^[2] ; K J,Minford ^[1] ; B S,Frank ^[2]

作者单位： Department of Pediatrics, Primary Children's Hospital, University of Utah, Salt Lake, UT, United States. ^[1] Department of Pediatrics, Children's Hospital of Colorado, University of Colorado, Aurora, CO, United States. ^[2]

关键词 SLC25A26 mutation TBX4 mutation pediatric pulmonary arterial hypertension pulmonary vasodilator pulmonary vasoreactivity riociguat targeted therapy

DOI 10.3389/fped.2022.1014922

PMID 36533232

发布时间 2022-12-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pediatrics

2022年10卷

1014922页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.

Frontiers in pediatrics

相似文献

Frontiers in pediatrics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.

Frontiers in pediatrics

相似文献

Frontiers in pediatrics

相关期刊

检索历史清除